Key Findings:  Researchers present clinical and preclinical evidence suggesting CBD and other cannabinoids have therapeutic effects in Parkinson's disease and L-DOPA-induced dyskinesia.
Type of Study:  Meta-analysis
Study Result:  Positive
Research Location(s):  Brazil
Year of Pub:  2019
Cannabinoids Studied:  Cannabidiol (CBD), Cannabinoid (unspecified), Synthetic Cannabinoid (unspecified)
Phytocannabinoid Source:  Not Applicable
Receptors Studied:  TRPs, PPARs
Ligands Studied:  Anti-inflammatory cytokines, Pro-inflammatory cytokines
Citation:  Junior NCF, et al. Cannabidiol and Cannabinoid Compounds as Potential Strategies for Treating Parkinson's Disease and L-DOPA-Induced Dyskinesia. Neurotox Res. 2020; 37:12-29. doi: 10.1007/s12640-019-00109-8
Authors:  Junior NCF, Dos-Santos-Pereira M, Guimarães FS, Del Bel E